1 unchanged sentence
Director and Executive Officer Trading Arrangements
−Removed: During the second quarter of 2024, none of our directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
+Added: During the third quarter of 2024, none of our directors or officers adopted , modified or terminated any contract, instruction or written plan for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
9 unchanged sentences
001-40440) filed on July 17, 2024).
−Removed: Sublease Agreement by and between the Company and GeneFab , LLC, dated as of May 7, 2024.
Amended and Restated ChEF Purchase Agreement, by and between Chardan Capital Markets LLC and Senti Biosciences, Inc., dated July 16, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
001-40440) filed on July 16, 2024).
−Removed: C onsulting Agreement by and between the Compan y and Deborah Knobelman , effect ive as of May 4, 2024.
−Removed: Consulting Agreement by and between the Company and Yvonne Li, effecti ve as of May 1 , 2024.
+Added: Sublease Agreement by and among the Company, BKPBIOTECH, Inc.
+Added: and JLSA2 Therapeutics, Inc., dated as of September 23, 2024.
+Added: S torage L icense Agreement by and among the Company, B KPBIOTECH, Inc.
+Added: and JLSA2 Therapeutics, Inc., dated as of September 23, 2024.
31.1* Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
18 unchanged sentences
A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 13 th day of August, 2024.
−Removed: August 13, 2024
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 14 th day of November, 2024.
+Added: November 14, 2024
SENTI BIOSCIENCES, INC.
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.